Indolent lymphoma · 6 regimens
Cost vs Efficacy · 2 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Cyclophosphamide and Fludarabine (FC) Variant #15 | — | R 14 005 | — | ~20.6 mo | — | ~8 | ~R 112 036 PFS proxy · indirect | 3 |
Fludarabine monotherapy Variant #05 | — | R 13 754 | 28d | ~16.5 mo | ~52.9 mo | ~12 | ~R 165 047 PFS proxy · indirect | 4 |
FND Variant #01 | — | R 12 357 | 28d | — | — | ~8 | ~R 98 858 indirect | — |
ProMACE-MOPP Variant #01 Partial | — | R 1 653 | 28d | — | — | ~8 | ~R 13 226 indirect | — |
COPA Variant #01 | — | R 1 019 | 28d | — | — | ~8 | ~R 8 156 indirect | — |
CVP Variant #01 | — | R 613 | 21d | — | — | ~2 | ~R 1 225 indirect | — |
6 of 6 regimens shown